Dosing Errors May Impact the Risk of rt-PA for Stroke: The Multicenter rt-PA Acute Stroke Survey

Journal of Stroke and Cerebrovascular Diseases

Volumn 13, Issue 1, 2004, Pages 35-40

  Messé, Steven R ^a   Tanne, David ^b   Demchuk, Andrew M ^c   Cucchiara, Brett L ^a   Levine, Steven R ^d   Kasner, Scott E ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c FOOTHILLS HOSPITAL   (Canada)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Intracranial hemorrhage; Medication errors; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BODY WEIGHT; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; MULTICENTER STUDY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCORING SYSTEM; STROKE;

EID: 1842584310     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2004.01.001     Document Type: Article

References (20)

1. Freedman JE, Becker RC, Adams JE, et al. Medication errors in acute cardiac care: An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke. Circulation 2002;106:2623-2629.
2. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: The Multicenter rt-PA Stroke Survey. Circulation 2002;105:1679-1685.
3. NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1588.
4. Levy DE, Brott TG, Haley EC, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994;25:291-297.
5. Brott TG, Haley EC, Levy DE, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered with 90 minutes. Stroke 1992;23:632-640.
6. Murphy SA, Gibson CM, Van de Werf F, et al. Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). Am J Cardiol 2002;90:51-54.
7. Hull RD, Raskob GE, Hirsch J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986;315:1109-1114.
8. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995;108:335S-351S.
9. Cannon CP. Thrombolysis medication errors: Benefits of bolus thrombolytic agents. Am J Cardiol 2000;85:17C-22C.
10. Richards CF, Cannon CP. Reducing medication errors: Potential benefits of bolus thrombolytic agents. Acad Emerg Med 2000;7:1285-1289.
11. Wang-Clow F, Fox NL, Cannon CP, et al. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator. Am Heart J 2001;141:33-40.
12. Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. Circulation 1991;83:448-459.
13. Gurwitz JH, Gore JM, Goldberg RJ, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med 1998;129:597-604.
14. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283:1145-1550.
15. Davenport J, Hanson SK, Altafullah IM, et al. tPA: A rural network experience. Stroke 2000;31:1457.
16. Kasner SE, Chalela JC, Luciano JM, et al. Reliability and validity of estimating the NIH Stroke Scale from medical records. Stroke 1999;30:1534-1537.
17. The NINDS rt-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109-2118.
18. Haley EC, Levy DE, Brott TG, et al. Urgent therapy for stroke: Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992;23:641-645.
19. Vailas L, Nitzke SA. Self-reported versus measured weight and height in an older adult meal program population. J Gerontol A Biol Sci Med Sci 1998;53:M481-M483.
20. Fernandes CM, Clark S, Price A, et al. How accurately do we estimate patients' weight in emergency departments? Can Fam Physician 1999;45:2373-2376.